Artivion, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
AORT
Artivion, INCArtivion, Inc. announced its second quarter 2026 financial results, reporting an 11% increase in total revenues to $125.8 million, but a net loss of $13.5 million.
NYSE
AORT
Artivion, INCArtivion reported strong first-quarter 2026 financial results, highlighted by an 18% revenue increase and the strategic acquisition of Endospan.
NYSE
AORT
Artivion, INCArtivion, Inc. announced significant revenue growth and a substantial reduction in debt for the third quarter and first nine months of 2025, driven by strong product sales and strategic financial restructuring.
NYSE
AORT
Artivion, INCArtivion, Inc. reported a 15% increase in total revenues for Q2 2025, reaching $113 million, while significantly reducing long-term debt through strategic financial maneuvers.
NYSE
AORT
Artivion, INC10-Q: Artivion Reports Mixed Q1 2025 Results: Revenue Up Slightly, Impacted by Cybersecurity Incident
Artivion's Q1 2025 results show a slight revenue increase but are impacted by a cybersecurity incident and changes in contingent consideration.
NYSE
AORT
Artivion, INCArtivion's Q3 2024 results show revenue growth driven by key product lines, offset by a net loss and increased interest expenses due to recent debt refinancing.
NYSE
AORT
Artivion, INCArtivion's Q2 2024 results show a revenue increase but a net loss, alongside strategic amendments to loan agreements.
NYSE
AORT
Artivion, INCArtivion's first quarter of 2024 saw a significant revenue increase of 17% year-over-year, driven by growth in all product and service categories.